SWOG clinical trial number
SWOG-8942
High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine Combined with Autologous Bone Marrow Rescue for Refractory or Relapsed Non-Hodgkin's Lymphoma
Closed
Phase
Accrual
100%
Published
Abbreviated Title
High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine Combined with Autologous Bone Marrow Rescue for Refractory or Relapsed Non-Hodgkin's Lymphoma
Activated
03/01/1990
Closed
12/15/1994
Research committees
Lymphoma
Publication Information Expand/Collapse
1998
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens-A Southwest Oncology Group trial.
1995
Autologous bone marrow transplantation (ABMT) for patients with diffuse non-Hodgkin's lymphoma: Value of augmented preparative regimens. A Southwest Oncology Group (SWOG) trial.
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
37%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
14%
Open
Phase